The University of Maryland, Baltimore (UMB) was awarded a $587,271 Project Grant from the Defense Health Agency, under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), to conduct research on "DUAL INHIBITION OF PARP AND IL-6 AS A NOVEL THERAPEUTIC APPROACH FOR BRCA-MUTATED TRIPLE-NEGATIVE BREAST CANCER." This research project will occur from July 1, 2024 to June 30, 2027. The Military Medical Research and Development program supports a broad range of biomedical research initiatives focused on improving healthcare for service members and veterans, with a particular emphasis on cancer, neurological disorders, and other priority military health issues.
Generated 8/13/24, 3:49 AM